Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ABITRAM Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABITRAM, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ABI3BP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABI3BP, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Wolman disease Indication Strategy Report 2026: LIPA, Trials and Deals
23 July 2026
2026 Wolman disease strategy: epidemiology, LIPA biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
8 min read
ABI3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABI3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ABI2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABI2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ABI1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABI1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ABHD18 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABHD18, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ABHD17C Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABHD17C, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ABHD17B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABHD17B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ABHD17A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABHD17A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Schindler disease Indication Strategy Report 2026: NAGA, Trials and Deals
23 July 2026
2026 Schindler disease strategy: epidemiology, NAGA biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
8 min read
ABHD16B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ABHD16B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.